Consistent with ERBB2-mediated tamoxifen resistance, trastuzumab effectively suppressed the growth of BCX1TamR1 tumors and prolonged the tumor-free survival (Fig. 5, H and I), while the parental BCX1 tumors were unresponsive to trastuzumab (fig. Here, ERBB2 is linked to neoplasm.